Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedNov 08, 2025
DataAggregated Company Financials
Companies541
  • 7D-0.6%
  • 3M15.9%
  • 1Y-1.1%
  • YTD15.0%

Last week, the Biotech industry hasn't moved much but Amgen is up 7.3% in that time. Furthermore, the industry has been flat for the past year as well. Looking forward, earnings are forecast to grow by 24% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 08 Nov 2025US$1.1tUS$163.2b-US$15,904,863,908.5716.2x-71.3x6.9x
Mon, 06 Oct 2025US$1.1tUS$163.5b-US$18,204,873,215.1716.7x-62.3x6.9x
Wed, 03 Sep 2025US$1.1tUS$163.5b-US$18,341,149,050.4115.4x-57.6x6.5x
Fri, 01 Aug 2025US$977.1bUS$155.6b-US$21,869,816,647.1615.7x-44.7x6.3x
Sun, 29 Jun 2025US$927.2bUS$156.0b-US$23,836,878,936.0917.2x-38.9x5.9x
Tue, 27 May 2025US$907.6bUS$156.0b-US$24,117,883,283.5915.6x-37.6x5.8x
Thu, 24 Apr 2025US$786.0bUS$119.2b-US$36,559,322,741.4119.7x-21.5x6.6x
Sat, 22 Mar 2025US$829.3bUS$118.6b-US$36,904,224,937.6920.4x-22.5x7x
Mon, 17 Feb 2025US$842.1bUS$116.6b-US$36,838,613,842.2117.6x-22.9x7.2x
Wed, 15 Jan 2025US$933.0bUS$149.4b-US$26,267,408,194.2516.7x-35.5x6.2x
Fri, 13 Dec 2024US$1.0tUS$150.0b-US$26,532,638,861.6317.1x-38.5x6.8x
Sun, 10 Nov 2024US$1.1tUS$149.6b-US$27,286,902,976.6116.5x-40.7x7.4x
Tue, 08 Oct 2024US$889.8bUS$113.1b-US$35,895,408,227.4020.8x-24.8x7.9x
Thu, 05 Sep 2024US$889.8bUS$113.1b-US$35,706,110,149.3423.3x-24.9x7.9x
Sat, 03 Aug 2024US$1.2tUS$165.9b-US$33,221,382,510.8425.9x-36.6x7.3x
Mon, 01 Jul 2024US$1.1tUS$164.4b-US$27,988,781,321.0728.5x-41x7x
Wed, 29 May 2024US$1.1tUS$164.6b-US$26,663,229,028.4727.2x-42.2x6.8x
Fri, 26 Apr 2024US$1.1tUS$164.2b-US$23,382,193,080.9720.1x-46x6.6x
Sun, 24 Mar 2024US$1.2tUS$164.3b-US$23,936,586,653.3521.4x-48.6x7.1x
Tue, 20 Feb 2024US$1.2tUS$169.1b-US$20,394,485,082.3215.7x-57.5x6.9x
Thu, 18 Jan 2024US$1.4tUS$204.8b-US$22,506,707,794.0018.8x-63.3x7x
Sat, 16 Dec 2023US$1.4tUS$204.7b-US$22,119,635,723.0019.2x-61x6.6x
Mon, 13 Nov 2023US$1.2tUS$204.5b-US$21,996,116,562.0018.5x-54.6x5.9x
Wed, 11 Oct 2023US$1.3tUS$207.4b-US$13,069,383,940.0017.3x-96.7x6.1x
Fri, 08 Sep 2023US$1.3tUS$207.5b-US$12,639,999,993.0017.3x-100.8x6.1x
Sun, 06 Aug 2023US$1.3tUS$210.2b-US$10,135,599,050.0015.6x-124.3x6x
Tue, 04 Jul 2023US$1.1tUS$186.3b-US$16,037,705,056.0013.4x-69.9x6x
Thu, 01 Jun 2023US$1.1tUS$185.9b-US$16,012,100,305.0011.4x-69.8x6x
Sat, 29 Apr 2023US$1.2tUS$197.1b-US$6,647,559,484.0013.7x-174.1x5.9x
Mon, 27 Mar 2023US$1.1tUS$199.3b-US$3,667,886,514.0013.4x-309x5.7x
Wed, 22 Feb 2023US$1.1tUS$202.5b-US$166,298,506.0016.4x-6829.5x5.6x
Fri, 20 Jan 2023US$1.2tUS$203.7bUS$1.8b14.2x658.6x5.7x
Sun, 18 Dec 2022US$1.2tUS$203.3bUS$1.6b14.4x712.9x5.7x
Tue, 15 Nov 2022US$1.1tUS$202.2bUS$1.1b14.9x1009.4x5.5x
Price to Earnings Ratio

1009.4x


Total Market Cap: US$1.1tTotal Earnings: US$1.1bTotal Revenue: US$202.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 23.2x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.5x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 6.9% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.99%
Healthcare0.55%
Biotech-0.62%
Biotech-0.62%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AMGN AmgenUS$320.207.3%
+US$11.8b		-1.6%PE24.6x
INCY IncyteUS$105.9813.4%
+US$2.5b		27.1%PE17.5x
ABBV AbbVieUS$219.160.5%
+US$2.2b		9.9%PE165x
MTSR MetseraUS$83.1831.9%
+US$2.1b		n/aPB19.5x
MDGL Madrigal PharmaceuticalsUS$489.2616.8%
+US$1.8b		39.5%PS15x

Latest News

ONC
US$319.97
BeOne Medicines
7D
3.1%
1Y
55.7%
GILD
US$118.84
Gilead Sciences
7D
-0.8%
1Y
23.1%
MDGL
US$489.26
Madrigal Pharmaceuticals
7D
16.8%
1Y
39.5%

MDGL: Future Revenue Leadership Will Depend On Therapy Adoption Amid Rising Competition

The analyst consensus price target for Madrigal Pharmaceuticals has increased by approximately $23 to $536, as analysts cite continued strength from Rezdiffra as well as improved long-term profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased price targets for Madrigal Pharmaceuticals, emphasizing Rezdiffra’s ongoing outperformance and supportive market dynamics, even as new competitors enter the F2-F3 MASH segment.
MRNA
US$24.54
Moderna
7D
-9.6%
1Y
-47.6%

MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties

Moderna's analyst price target was reduced from $18 to $15, as analysts pointed to lower US vaccination trends and ongoing regulatory uncertainties that are impacting the outlook for its vaccine franchises. Analyst Commentary Recent analyst notes have reflected both cautious and optimistic perspectives on Moderna's outlook.
NBIX
US$152.37
Neurocrine Biosciences
7D
6.4%
1Y
21.2%
CAI
US$25.61
Caris Life Sciences
7D
-14.9%
1Y
n/a
AMGN
US$320.20
Amgen
7D
7.3%
1Y
-1.6%
BHVN
US$8.26
Biohaven
7D
-52.0%
1Y
-84.6%
QURE
US$27.79
uniQure
7D
-58.9%
1Y
256.7%
MTSR
US$83.18
Metsera
7D
31.9%
1Y
n/a
SLNO
US$47.70
Soleno Therapeutics
7D
-29.0%
1Y
-16.4%
INCY
US$105.98
Incyte
7D
13.4%
1Y
27.1%
VRTX
US$409.47
Vertex Pharmaceuticals
7D
-3.8%
1Y
-20.8%
ABBV
US$219.16
AbbVie
7D
0.5%
1Y
9.9%
REGN
US$657.53
Regeneron Pharmaceuticals
7D
0.9%
1Y
-20.6%
ALNY
US$442.70
Alnylam Pharmaceuticals
7D
-2.9%
1Y
59.6%